14 News & Press Releases found
Carmat News
-
CARMAT anticipates implants of its Aeson artificial heart to resume in October 2022
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical needby providing a therapeuticalternative to people suffering from end-stage biventricular heart ...
-
CARMAT announces the completion of its investigations on previously identified quality issues
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart ...
-
CARMAT voluntarily suspends Aeson implantations on a temporary basis
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart ...
-
CARMAT announces the first implant of its Aeson total artificial heart in The Netherlands
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart ...
-
CARMAT announces the publication of an article on the Aeson’s autoregulation system in the ASAIO Journal
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart ...
-
CARMAT receives final approval from the patient protection committee for the use of the commercial version of the Aeson heart in the EFICAS study in France
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart ...
-
CARMAT appoints Ivo Simundic as Sales director for the DACH region to support the deployment of the Aeson artificial heart in Germany, Austria and Switzerland
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart ...
-
CARMAT announces a new commercial implant of its Aeson artificial heart at University Medical Center Schleswig-Holstein in Kiel, Germany
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the ...
-
CARMAT announces the second center implanting its total artificial heart in the United States
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study. CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most ...
-
First human implant of the Aeson artificial heart in Germany
The implant was performed at Hannover Medical School. Paris, July 26, 2021 – 6:00 pm CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic ...
-
Carmat announces the issuance of a second tranche of equity warrants within the framework of its contingent equity line with Kepler Cheuvreux
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage ...
-
CARMAT obtains a €1.4 million grant as part of the “Industrial recovery plan – Strategic sectors” call for projects
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing ...
-
CARMAT receives FDA approval to use the new version of its artificial heart in the US Early Feasibility Study (EFS)
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart ...
-
Carmat outlines commercial and development plan for its total artificial heart
Addressable market in the bridge-to-transplant indication of more than 2,000 patients a year in Europe Company prepares for commercial launch in Q2 2021, with initial focus on Germany and France Robust clinical plan to support adoption and sales ...